Immune responses to adenoviruses: Viral evasion mechanisms and their implications for the clinic

Current Opinion in Immunology

Volumn 11, Issue 4, 1999, Pages 380-386

  Wold, William SM ^a   Doronin, Konstantin ^a   Toth, Karoly ^a   Kuppuswamy, Mohan ^a   Lichtenstein, Drew L ^a   Tollefson, Ann E ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FAS LIGAND; INTERFERON; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; TUMOR NECROSIS FACTOR; VIRUS PROTEIN;

ADENOVIRUS; APOPTOSIS; CYTOTOXIC T LYMPHOCYTE; GENE THERAPY; HUMAN; NONHUMAN; REVIEW; VIRUS CELL INTERACTION; VIRUS IMMUNITY; VIRUS INFECTION;

EID: 0033178526     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-7915(99)80064-8     Document Type: Article

References (50)

1. Molnar-Kimber K, Sterman DH, Chang Y, Kang J, Elbash M, Lanuti M, Elshami A, Gelfand K, Wilson JM, Kaiser LR, Albelda SM: Impact of preexisting and induced humoral and cellular immune responses in an adenovirus-based gene therapy phase I clinical trial for localized mesothelioma. Hum Gene Ther 1998, 9:2121-2133. Little is known about the immune response in humans to adenovirus gene therapy vectors. This paper shows that out of 21 patients, most had preexisting neutralizing antibodies and had peripheral blood mononuclear cells that proliferated in response to adenovirus. These antibodies did not preclude transgene (herpes simplex virus thymidine kinase) expression. Vector instillation induced high titers of neutralizing antibodies against adenovirus.
2. Prives C: Signaling to p53: Breaking the MDM2-p53 circuit. Cell 1998, 95:5-8.
3. Martin MED, Berk AJ: Adenovirus E1B 55K represses p53 activation in vitro. J Virol 1998, 72:3146-3154.
4. Chinnadurai G: Control of apoptosis by human adenovirus genes. Semin Virol 1998, 8:399-408.
5. White E: Regulation of apoptosis by adenovirus E1A and E1B oncogenes. Semin Virol 1998, 8:505-513.
6. Yasuda M, Theodorakis P, Subramanian T, Chinnadurai G: Adenovirus E1B-19K/BCL-2 interacting protein BNIP3 contains a BH3 domain and a mitochondrial targeting sequence. J Biol Chem 1998, 273:12415-12421.
7. L interacts with Apaf-1 and inhibits Apaf-1 dependent caspase-9 activation. Proc Natl Acad Sci USA 1998, 95:4386-4391.
8. Adams JM, Cory S: The Bcl-2 protein family: Arbiters of cell survival. Science 1998, 281:1322-1326. This is an excellent and provocative review.
9. Mathews MB, Shenk T: Adenovirus virus-associated RNA and translation control. J Virol 1991, 65:5657-5662.
10. Leonard GT, Sen GC: Effects of adenovirus E1A protein on interferon-signaling. Virology 1996, 224:25-33.
11. Wold WSM, Tollefson AE, Hermiston TW: E3 transcription unit of adenovirus. In The Molecular Repertoire of Adenoviruses, Edn 1. Edited by Doerfler W, Bohm R Heidelberg: Springer-Verlag; 1995:237-274.
12. Deryckere F, Burgert H-G: Tumor necrosis factor alpha induces the adenovirus early 3 promoter by activation of NF-κB. J Biol Chem 1996, 271:30249-30255.
13. Jackson MR, Nilsson T, Peterson PA: Retrieval of transmembrane proteins to the endoplasmic reticulum. J Cell Biol 1993, 121:317-333.
14. Beier DC, Cox JH, Vining DR, Cresswell P, Engelhard VH: Association of human class I MHC alleles with the adenovirus E3/19K protein. J Immunol 1994, 152:3862-3872.
15. Feuerbach D, Etteldorf S, Ebenau-Jehle C, Abastado J-P, Madden D, Burgert H-G: Identification of amino acids within the MHC molecule important for the interaction with the adenovirus protein E3-19K. J Immunol 1994, 153:1626-1636.
16. Shisler J, Duerksen-Hughes P, Hermiston TW, Wold WSM, Gooding LR: Induction of susceptibility to TNF by adenovirus E1A is dependent upon binding to either p300 or p105-Rb and induction of DNA synthesis. J Virol 1996, 70:68-77.
17. Cook JL, Krantz CK, Routes BA: Role of p300-family proteins in E1A oncogene induction of cytolytic susceptibility and tumor cell rejection. Proc Natl Acad Sci USA 1996, 93:13985-13990.
18. Nagata S: Apoptosis by death factor. Cell 1997, 88:355-365.
19. Mariani SM, Krammer PH: Surface expression of TRAIL/Apo-2 ligand in activated mouse T and B cells. Eur J Immunol 1998, 28:1492-1498.
20. Ashkenazi A, Dixit VM: Death receptors: Signaling and modulation. Science 1998, 281:1305-1308.
21. Chaudhary PM, Eby M, Jasmin A, Bookwalter A, Murray J, Hood L: Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-kB pathway. Immunity 1997, 7:821-830.
22. Griffith TS, Rauch CT, Smolak PJ, Waugh JY, Boiani N, Lynch DH, Smith CA, Goodwin RG, Kubin MZ: Functional analysis of TRAIL receptors using monoclonal antibodies. J Immunol 1999, 162:2597-2605.
23. Imai Y, Kimura T, Murakami A, Yajima N, Sakamaki K, Yonehara S: The CED-4-homologous protein FLASH is involved in Fas-mediated activation of caspase-8 during apoptosis. Nature 1999, 398:777-785. This paper identifies a new protein, FLASH, that is a component of the DISC. FLASH contains a death effector domain (DED) like sequence that interacts with the DED of Procaspase 8 and it contains a CED-4/Apaf-1 like sequence that mediates oligomerization. FLASH may mediate the ability of Fas or FADD to activate Procaspase 8. FLASH interacts with E1B-19K and overcomes its ability to inhibit Fas induced apoptosis. The work provides further insight into the mechanism of action of E1B-19K.
24. Hsu H, Huang J, Shu H-B, Baichwal V, Goeddel DV: TNF-dependent recruitment of the protein kinase RIP to the TNF receptor-1 signaling complex. Immunity 1996, 4:387-396.
25. Kelliher MA, Grimm S, Ishida Y, Kuo F, Stanger BZ, Leder P: The death domain kinase RIP mediates the TNF-induced NF-κB signal. Immunity 1998, 8:297-303. This paper describes data from RIP knockout mice, indicating that a primary function of RIP is to mediate activation of NFκB.
26. Tollefson AE, Hermiston TW, Lichtenstein DL, Colle CF, Tripp RA, Dimitrov T, Toth K, Wells CE, Doherty PC, Wold WSM: Forced degradation of Fas inhibits apoptosis in adenovirus-infected cells. Nature 1998, 392:726-730. This paper shows that the adenovirus E3 RID protein inhibits Fas induced apoptosis by causing Fas to be internalized from the cell surface and degraded in lysosomes. This is the first demonstration that Fas can be internalized and degraded in lysosomes.
27. Gooding LR, Ranheim TS, Tollefson AE, Aquino L, Duerksen-Hughes P, Horton TM, Wold WS: The 10,400- and 14,500-dalton proteins encoded by region E3 of adenovirus function together to protect many but not all mouse cell lines against lysis by tumor necrosis factor. J Virol 1991, 65:4114-4123.
28. Shisler J, Yang C, Walter B, Ware CF, Gooding LR: The adenovirus E3-10.4K/14.5K complex mediates loss of cell surface Fas (CD95) and resistance to Fas-induced apoptosis. J Virol 1997, 71:8299-8306.
29. Elsing A, Burgert H-G: The adenovirus E3/10.4K-14.5K proteins down-modulate the apoptosis receptor Fas/Apo-1 by inducing its internalization. Immunology 1998, 95:10072-10077.
30. Tollefson AE, Stewart AR, Yei SP, Saha SK, Wold WS: The 10,400-and 14,500-dalton proteins encoded by region E3 of adenovirus form a complex and function together to down-regulate the epidermal growth factor receptor. J Virol 1991, 65:3095-3105.
31. Kuivinen E, Hoffman BL, Hoffman PA, Carlin CR: Structurally related class I and class II receptor protein tyrosine kinases are down-regulated by the same E3 protein coded for by human group C adenoviruses. J Cell Biol 1993, 120:1271-1279.
32. Ohno H, Aguilar RC, Yeh D, Taura D, Saito T, Bonifacino JS: The medium subunits of adaptor complexes recognize distinct but overlapping sets of tyrosine-based sorting signals. J Biol Chem 1998, 273:25915-25921.
33. 2 to membranes. J Virol 1997, 71:2830-2837.
34. 2. J Biol Chem 1997, 272:16709-16712.
35. Krajcsi P, Dimitrov T, Hermiston TW, Tollefson AE, Ranheim TS, Vande Pol SB, Stephenson AH, Wold WSM: The adenovirus E3-14.7K protein and the E3-10.4K/14.5K complex of proteins, which independently inhibit Tumor Necrosis Factor (TNF)-induced apoptosis, also independently inhibit TNF-induced release of arachidonic acid. J Virol 1996, 70:4904-4913.
36. 2 is required for the lysis of adenovirus-infected cells by tumor necrosis factor. J Virol 1996, 70:8502-8507.
37. Gooding LR, Elmore LW, Tollefson AE, Brady HA, Wold WS: A 14,700 MW protein from the E3 region of adenovirus inhibits cytolysis by tumor necrosis factor. Cell 1988, 53:341-346.
38. Chen P, Tian J, Kovesdi I, Bruder JB: Interaction of the adenovirus 14.7K protein with FLICE inhibits Fas ligand-induced apoptosis. J Biol Chem 1998, 273:5815-5820.
39. Li Y, Kang J, Horwitz MS: Interaction of an adenovirus E3 14.7 kilodalton protein with a novel tumor necrosis factor alpha-inducible cellular protein containing leucine zipper domains. Mol Cell Biol 1998, 18:1601-1610. This reports the discovery of FIP-2, a protein that binds to E3-14.7K and overcomes the ability of E3-14.7K to inhibit apoptosis. This is the first connection of E3-14.7K to the putative RIP-FIP pathway.
40. Li Y, Kang J, Friedman J, Tarassishin L, Ye J, Kovalenko A, Wallach D, Horwitz MS: Identification of a cell protein (FIP-3) as a modulator of NF-κB activity and as a target of an adenovirus inhibitor of tumor necrosis factor α-induced apoptosis. Immunology 1999, 96:1042-1047. This paper identifies a new and interesting protein, FIP-3, that binds to E3-14.7K and plays a role in TNF signal transduction - leading to apoptosis and activation of NFκB. FIP-3 binds to RIP and NIK. The work provides a major insight into how E3-14.7K may function.
41. Li Y, Kang J, Horwitz MS: Interaction of an adenovirus 14.7-kilodalton protein inhibitor of tumor necrosis factor alpha cytolysis with a new member of the GTPase superfamily of signal transducers. J Virol 1997, 71:1576-1582.
42. Gooding LR, Aquino L, Duerksen-Hughes PJ, Day D, Horton TM, Yei SP, Wold WS: The E1B 19,000-molecular-weight protein of group C adenoviruses prevents tumor necrosis factor cytolysis of human cells but not of mouse cells. J Virol 1991, 65:3083-3094.
43. Perez D, White E: E1B 19K inhibits Fas-mediated apoptosis through FADD-dependent sequestration of FLICE. J Cell Biol 1998, 141:1255-1266. E1B-19K is known to be a functional homolog of BCL-2. This paper shows that E1B-19K can also inhibit Fas induced apoptosis at another level, namely via FADD and Procaspase 8 in the DISC.
44. Sparer T, Tripp RA, Dillehay DL, Hermiston TW, Wold WSM, Gooding LR: The role of adenovirus early region 3 proteins (gp19k, 10.4K, 14.5K, and 14.7K) in a murine pneumonia model. J Virol 1996, 70:2431-2439.
45. Harrod KS, Hermiston TW, Trapnell BC, Wold WSM, Whitsett JA: Lung-specific expression of E3-14.7K in transgenic mice attenuates adenoviral vector-mediated lung inflammation and enhances transgene expression. Hum Gene Ther 1998, 9:1885-1898. This paper shows that E3-14.7K expressed in the lungs of transgenic mice strongly inhibits the inflammatory and pathogenic response to adenovirus. The work therefore proves that E3-14.7K has anti-inflammatory properties in vivo and it underscores the possibility of using E3-14.7K in gene therapy.
46. Ilan Y, Droguett G, Chowdhury NR, Li Y, Sengupta K, Thummala NR, Davidson A, Chowdhury JR, Horwitz MS: Insertion of the adenoviral E3 region into a recombinant viral vector prevents antiviral humoral and cellular immune responses and permits long-term gene expression. Proc Natl Acad Sci USA 1997, 94:2587-2592.
47. Chirmule N, Moscioni AD, Qian Y, Qian R, Chen Y, Wilson JM: Fas-Fas ligand interactions play a major role in effector functions of cytotoxic T lymphocytes after adenovirus vector-mediated gene transfer. Hum Gene Ther 1999, 10:259-269.
48. Bruder JT, Jie T, McVey DL, Kovesdi I: Expression of gp19K increases the persistence of transgene expression from an adenovirus vector in the mouse lung and liver. J Virol 1997, 71:7623-7628.
49. Efrat S, Fejer G, Brownlee M, Horwitz MS: Prolonged survival of pancreatic islet allografts mediated by adenovirus immunoregulatory transgenes. Proc Natl Acad Sci USA 1995, 92:6947-6951.
50. Von Herrath MG, Efrat S, Oldstone MBA, Horwitz MS: Expression of adenovirus E3 transgenes in β cells prevents autoimmune diabetes. Proc Natl Acad Sci USA 1997, 94:9808-9813.